The breakthrough that made therapeutic mRNA possible was chemical, not viral: modifying the nucleosides so the body does not reject the synthetic message as a threat. US12226471B2 - "Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus," issued February 18, 2025 to The Trustees of the University of Pennsylvania (inventors include Drew Weissman) - claims that chemistry applied to an HCV vaccine.
The foundational limitation is the nucleoside modification. Unmodified mRNA triggers a strong innate immune response that degrades it and causes toxicity; substituting modified nucleosides (the Kariko-Weissman insight) tames that response, letting the mRNA persist and express its antigen. The claim builds on that modified-mRNA core, paired with an HCV antigen and lipid-nanoparticle delivery.
The CPC profile shows all three elements: A61K 39/12 (viral vaccine), A61K 39/29 (hepatitis vaccine), A61K 9/127 (liposome/LNP), with the vaccine-formulation tags (A61K 2039/5258, /53, /55555). The antigen targets HCV, the delivery is LNP, and the enabling chemistry is the modified nucleoside - three layers in one therapeutic claim.
Why is the nucleoside modification the load-bearing piece? Because it is the platform-enabling invention from which the whole modern mRNA field descends. A claim resting on nucleoside-modified mRNA sits close to the foundational chemistry; its scope and the prior art around it are defined by that modification more than by the specific HCV antigen, which is the interchangeable part of the platform.
For the landscape, Penn's nucleoside-modification estate is one of the most fundamental positions in all of mRNA therapeutics - it underlies the COVID vaccines and the broader platform. A freedom-to-operate read for any modified-mRNA product has to account for this foundational chemistry layer, independent of the specific antigen or delivery formulation a given vaccine uses.